KKG PUBLICATIONS
  • Home
  • Journals
    • BUSINESS & ADMINISTRATIVE STUDIES
    • HUMANITIES, ARTS & SOCIAL SCIENCES
    • TECHNOLOGY & ENGINEERING STUDIES
    • APPLIED SCIENCES
    • MEDICAL SCIENCES
  • Publishing Ethics
  • Privacy Policy
  • Crossmark Policy
  • Contact Us
  • Home
  • Journals
    • BUSINESS & ADMINISTRATIVE STUDIES
    • HUMANITIES, ARTS & SOCIAL SCIENCES
    • TECHNOLOGY & ENGINEERING STUDIES
    • APPLIED SCIENCES
    • MEDICAL SCIENCES
  • Publishing Ethics
  • Privacy Policy
  • Crossmark Policy
  • Contact Us
  • https://evolua.ispcaala.com/
  • http://pewarta.org/styles/
  • https://perhepi.org/
  • https://portal-indonesia.id/
  • https://nursahid.com/
  • https://singmanfaat.jabarprov.go.id/
  • https://sindika.co.id/
  • https://cirebonkerja.id/
  • https://klikoku.id/
  • https://iii.cemacyc.org/minicursos/
  • https://iv.cemacyc.org/creditos/
  • https://iv.cemacyc.org/
  • https://www.winteriorsdecor.com/
  • https://e-journal.polnes.ac.id/
  • https://dap.sumbarprov.go.id/
  • https://dinkes.sarolangunkab.go.id/
  • https://bappeda.sarolangunkab.go.id/
  • https://sipena.rsjrw.id/
  • https://slims.assunnah.ac.id/
  • https://ojs.as-pub.com/
  • https://techniumscience.com/

A Survey on the Prevalence of Hepatitis B Virus and Predisposing Factors among Blood Donors in Two General Hospitals in Jigawa State Nigeria



   Volume 3, Issue 2
SALISU A. , MUKTAR, M. D., SALISU, A. I., ABDULHADI, Y., M. UMAR

Published online: 14 July 2017

Article Views: 41

Abstract

This research was carried out to determine the prevalence state of Hepatitis B infection and predisposing factors among blood donors in Dutse and Gumel General Hospitals, Jigawa State, Nigeria. Five hundred and forty-six (546) blood samples were aseptically collected from consenting donors at two hospitals. Two hundred and seventy-three (273) samples were screened from each General Hospital for Hepatitis B Surface Antigen (HBsAg) using third generation enzyme immunoassay HBsAg kits. Out of 273 samples from Dutse General Hospital, 260 were males, and 13 were females while in Gumel General Hospital, 264 were males, and 9 were females. The prevalence rates in the two General Hospitals were 36 and 27 respectively. The peak age specific HBsAg sero-positivity occurred in the aged range of 31-40yrs and 21-30yrs for Dutse and Gumel General Hospitals respectively. Commercial donors constitute highest percentage of blood donors in the two Hospitals; 25% and 20% respectively. The finding indicates that there is no significant difference between gender and the occurrence of the infection among blood donors attending two General Hospitals p > 0.05. The result confirmed that there is no significant difference between the two hospitals based on the Hepatitis B infection at p > 0.05. Among the predisposing factors analysed statistically, the result shows that there is significant difference p < 0.05 between the level of education, occupational status, donors with history of Alcohol consumption, and the occurrence of Hepatitis B surface Antigen in both hospitals but there is no significant difference p > 0.05 between the Hepatitis B Virus (HBV) vaccination status and the occurrence of HBsAg among donors in both hospitals, so it is important to make thorough investigation among blood donors before transfusion of blood, because transfusion of blood saves life, but recipients are at high risk of contracting Hepatitis B virus infections through transfusion of infected blood and blood products. Mass screening, immunization against the virus, and public health education to enlighten the populace about infection and the routes of transmission are recommended.

Reference

  1. D. Lavanchy, “Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 97-107, 2004.
  2. P. Van Damme and K. Van Herck, “A review of the long-term protection after Hepatitis A and B vaccination,” Travel Medicine
    and Infectious Disease, vol. 5, no. 2, pp. 79-84, 2007.
  3. A. S. Lok and B. J. McMahon, “Chronic Hepatitis B,” The New England Journal of Medicine, vol. 346, no. 22, pp. 1682-1683,
    2002.
  4. World Health Organization. (2009). Department of communicable disease surveillance and response [Online]. Available:
    https://goo.gl/CxjBKa
  5. World Health Organization. (2011). Updated U.S. public health service guidelines for the management of occupational exposures
    to HBV, HCV, and HIV and recommendations for post exposure prophylaxis [Online]. Available: https://goo.gl/gteKc6
  6. R. Williams, “Global challenges in liver disease,” Hepatology, vol. 44, no. 3, pp. 521-526, 2006.
  7. J. H. Kao and D. S. Chen, “Global control of Hepatitis B virus infection,” The Lancet Infectious Diseases, vol. 2, no. 7, pp.
    395-403, 2002.
  8. M. J. Alter, “Epidemiology and prevention of Hepatitis B,” In Seminars in Liver Disease, Thieme Medical Publishers, New
    York, NY, vol. 23, no. 01, pp. 039-046, 2003.
  9. Z. Shi, Y. Yang, H. Wang, L. Ma, A. Schreiber, X. Li, W. Sun, X. Zhao, X. Yang, L. Zhang, W. Lu, J. Teng and Y. An,
    “Breastfeeding of newborns by mothers carrying Hepatitis B virus: A meta-analysis and systematic review,” Archives of
    Pediatrics and Adolescent Medicine, vol. 165, no. 9, pp. 837-846, 2011.
  10. A. Kay and F. Zoulim, “Hepatitis B virus genetic variability and evolution,” Virus Research, vol. 127, no. 2, pp. 164-176.
  11. J. L. Dienstag, “Hepatitis B virus infection,” New England Journal of Medicine, vol. 359, no. 14, pp. 1486-1500, 2008.
  12.  D. Ganem and A. M. Prince, “Hepatitis B virus infection-natural history and clinical consequences,” New England Journal of
    Medicine, vol. 350, no. 11, pp. 1118-1129, 2004.
  13. R. P. Beasley, C. C. Lin, L. Y. Hwang and C. S. Chien, “Hepatocellular carcinoma and Hepatitis B virus: A prospective study
    of 22 707 men in Taiwan,” The Lancet, vol. 318, no. 8256, pp. 1129-1133, 1981.
  14. D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Estimating the world cancer burden: Globocan 2000,” International Journal of
    Cancer, vol. 94, no. 2, pp. 153-156, 2001.
  15. B. Custer, S. D. Sullivan, T. K. Hazlet, U. Iloeje, D. L. Veenstra and K. V. Kowdley, “Global epidemiology of Hepatitis B
    virus,” Journal of Clinical Gastroenterology, vol. 38, no. 10, pp. S158-S168, 2004.
  16. P. Pisani, D. M. Parkin, F. Bray and J. Ferlay, “Estimates of the worldwide mortality from 25 cancers in 1990,” International
    Journal of Cancer, vol. 83, no. 1, pp. 18-29, 1999.
  17. World Health Organization. (2012). Fact sheet, Hepatitis B [Online]. Available: https://goo.gl/F6SwPm
  18. O. A. Ejele, C. A. Nwauche and O. Erhabor, “The prevalence of Hepatitis B surface antigenaemia in HIV positive patients in
    the Niger Delta Nigeria,” Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria,
    vol. 13, no. 2, pp. 175-179, 2003.
  19. World Health Organization. (2010). Department of communicable diseases surveillance and response [Online]. Available:
    https://goo.gl/CxjBKa
  20. D. Glebe and S. Urban, “Viral and cellular determinants involved in hepadnaviral entry,” World Journal of Gastroenterology,
    vol. 13, no. 1, pp. 22-38, 2007.
  21. World Gazetteer. (2007). Geography of Nigeria [Online]. Available: https://goo.gl/Z1czvT
  22. C. G. Schuttler, N. Fiedler, K. Schmidt, R. Repp, W. H. Gerlich and S. Schaefer, “Suppression of Hepatitis B virus enhancer 1
    and 2 by Hepatitis C virus core protein,” Journal of Hepatology, vol. 37, no. 6, pp. 855-862, 2002.
  23. K. M. Weinberger, T. Bauer, S. Bohm and W. Jilg, “High genetic variability of the group-specific a-determinant of Hepatitis
    B Virus Surface Antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking
    detectable HBsAg in serum,” Journal of General Virology, vol. 81, no. 5, pp. 1165-1174, 2000.
  24. A. A. Wagner, V. Loustaud-Ratti, I. Chemin, P. Weinbreck, F. Denis and S. Alain, “Double Hepatitis B virus infection in
    a patient with HIV/Hepatitis C virus coinfection and ‘anti-HBc alone’ as serological pattern,” European Journal of Clinical
    Microbiology & Infectious Diseases, vol. 24, no. 9, pp. 623-627, 2005.
  25. Y. Waheed, U. Saeed, S. Z. Safi, W. N. Chaudhry and I. Qadri, “Awareness and risk factors associated with barbers in transmission
    of Hepatitis B and C from Pakistani population: Barber’s role in viral transmission,” Asian Biomedicine Journal, vol.
    4, no. 3, pp. 435-442, 2010.
  26. O. M. David, A. O. Oluduro, A. B. Ariyo, D. Ayeni and O. Famurewa, “Sero-epidemiological survey of Hepatitis B surface
    antigenaemia in children and adolescents in Ekiti State, Nigeria,” Journal of Public Health and Epidemiology, vol. 5, no. 1,
    pp. 11-14, 2013.
  27. L. A. Eller, M. A. Eller, B. Ouma, P. Kataaha, D. Kyabaggu, R. Tumusiime and H. Kibuuka, “Reference intervals in healthy
    adult Ugandan blood donors and their impact on conducting international vaccine trials,” PLOS One, vol. 3, no. 12, pp. 1-6,
    2008.
  28. C. O. Imarengiaye, M. E. Enosolease, P. E. Iribhogbe and A. E. Ehigiegba, “Risk of transfusion-transmitted Hepatitis C virus
    in a tertiary hospital in Nigeria,” Public Health, vol. 120, no. 3, pp. 274-278, 2006.
  29. S. I. Gan, S. M. Devlin, N. W. Scott-Douglas and K. W. Burak, “Lamivudine for the treatment of membranous glomerulopathy
    secondary to chronic Hepatitis B infection,” Canadian Journal of Gastroenterology and Hepatology, vol. 19, no. 10, pp.
    625-629, 2005.

To Cite this article

A. Salisu, M. D. Muktar, A. I. Salisu, Y. Abdulhadi and M. Umar, “A survey on the prevalence of Hepatitis B virus and predisposing factors among blood donors in two general hospitals in Jigawa State Nigeria,” International Journal of Health and Medical Sciences, vol. 3, no. 2, 29-37, 2017.



© 2020. KKG Publications
Calle Alarcon 66, Sant Adrian De Besos 08930, Barcelona Spain | 00 34 610 911 348
About Us | Contact Us | Feedback

Search